Ipamorelin + CJC-1295: early effects

This article is educational. Ipamorelin and CJC-1295 (no DAC) are not approved medicines anywhere in the world. Neither the FDA, the EMA, the MHRA, nor any national agency we cover has authorised them for human use. Both are banned by WADA under section S2. This page describes what published research reports. It is not medical advice, and nothing here should guide a decision about whether or how to use these compounds. Talk to a clinician who knows your situation.

Posts about starting ipamorelin combined with CJC-1295 (no DAC) frequently mention one early observation: noticeably better sleep, sometimes within the first two or three nights. Whether that observation has a plausible biological basis, and what the wider literature says about the GH-axis effects of this combination, is what this article covers.

Two different mechanisms acting on the same axis

Ipamorelin is a synthetic pentapeptide that acts on the growth-hormone secretagogue receptor (GHS-R), sometimes called the ghrelin receptor. It mimics the action of ghrelin, prompting the pituitary to release a pulse of growth hormone^[1]. CJC-1295 without DAC, also called MOD-GRF(1-29), is a modified 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on the same pituitary cells and tells them to produce and release GH through a separate signalling pathway^[3].

Because they work at different receptors, the two signals can add up. Combining a GHRH analogue with a GHRP is a well-described pharmacological strategy for amplifying GH output beyond what either signal alone produces. The principle is established in preclinical pharmacology. It does not constitute evidence that the combination is safe or beneficial in humans.

What ipamorelin does differently from earlier GHRPs

Earlier growth-hormone-releasing peptides such as GHRP-6 and GHRP-2 raise cortisol and ACTH alongside GH, which limits their clinical appeal. A 1998 study characterising ipamorelin specifically tested this: at doses more than 200 times the effective dose for GH release, ipamorelin did not raise ACTH or cortisol levels significantly above those seen after GHRH stimulation alone^[1]. The authors described it as the first GHRP-receptor agonist with a selectivity profile for GH release similar to that of GHRH itself.

Pharmacokinetic work in human volunteers found that a single dose of ipamorelin produces one episode of GH release, peaking roughly 40 minutes after injection, with a terminal half-life of about two hours^[2]. The GH pulse clears after that window. This short duration is why users typically inject ipamorelin multiple times per day rather than once.

What CJC-1295 without DAC adds

CJC-1295 without DAC is a shorter-acting version of the original CJC-1295 compound. The original carries a drug-affinity complex (DAC) that lets it bind circulating albumin, extending the half-life from minutes to roughly six to eight days^[3]. The version without DAC acts more like native GHRH: it raises GH within a pulse window but does not persist for days.

The published human data for CJC-1295 comes from studies of the DAC version. In healthy adults, a single injection produced dose-dependent increases in mean GH concentrations of two- to ten-fold lasting six days or more, and IGF-1 increases of 1.5- to 3-fold lasting nine to eleven days^[3]. A separate study found that even during sustained CJC-1295 (DAC) stimulation, GH pulsatility was preserved: the normal burst-and-trough pattern continued, but trough GH levels rose 7.5-fold and mean GH concentration rose 46%^[4]. No serious adverse reactions were reported in either trial.

There are no equivalent controlled trials for CJC-1295 without DAC in humans. Its pharmacokinetics are assumed to differ from the DAC version based on structural differences, but direct human data showing the size or duration of its GH or IGF-1 effects has not been published.

The sleep connection: what the literature says

Growth hormone is secreted in its largest amounts during slow-wave (deep) sleep, typically in the first hours of the night. The relationship runs in both directions: GH pulses during sleep, and disrupting GH signalling can affect sleep architecture. Some GH secretagogues, including MK-677 (ibutamoren), have been shown in controlled trials to increase slow-wave sleep duration. No controlled trial has tested whether ipamorelin or CJC-1295 (without DAC) specifically improves sleep quality in humans.

The community-reported observation of better sleep within the first days of starting ipamorelin and CJC-1295 is plausible on mechanistic grounds, given the relationship between GH pulsatility and sleep. It is not supported by controlled data for these specific compounds. Sleep improvement could also reflect expectation effects, changes in activity or behaviour coinciding with starting a protocol, or placebo responses.

Preclinical data on the combination

A 2026 sports medicine review summarising injectable peptide evidence noted that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in a murine model of glucocorticoid-induced muscle loss^[6]. This rodent finding suggests the combination may have effects on muscle that neither compound alone produces as strongly. The same review emphasised that indications, dosing, frequency, and duration of treatment remain unknown for these peptides, and that no human orthopaedic data supports clinical use recommendations.

A preclinical study reported that ipamorelin produced dose-dependent increases in longitudinal bone growth in rats, with growth rate rising from 42 to 52 micrometres per day across the dose range tested^[5]. The same study found no significant change in serum IGF-1 levels, an unusual finding for a GH-releasing compound that may reflect measurement timing or treatment duration.

What is not known

The human evidence base for this combination is thin. There are no randomised controlled trials testing ipamorelin in humans for any indication. The CJC-1295 human data covers the DAC version at doses used in an early-phase pharmaceutical programme that stalled after 2006. No Phase 2 or Phase 3 efficacy trial for either compound has been completed.

The safety profile of repeated long-term use is uncharacterised. Short-term tolerability in healthy adults, at the doses studied, appeared acceptable in the CJC-1295 trials. What happens with sustained use across months or years, in the dose ranges circulated online, is not documented in peer-reviewed literature.

Regulatory position

Neither ipamorelin nor CJC-1295 has a marketing authorisation from the FDA, the EMA, the MHRA, or any of the seven national agencies this site covers. In the United States, ipamorelin's eligibility for pharmacy compounding under section 503A was reviewed by the FDA's Pharmacy Compounding Advisory Committee in October 2024. Both compounds are prohibited by WADA under section S2, covering growth-hormone secretagogues and GHRH analogues^[7]. That prohibition applies in- and out-of-competition for athletes subject to testing.